Clinical Trial Update: 24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia [Phase 3]

View source ↗

Summary

A 24-week open-label extension to a randomized, double-blind, placebo-controlled Phase 3 trial assessing the safety and tolerability of flexible doses of extend…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Invega ER (paliperidone extended-release)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED